Metagenomi (MGX) Fundamental Analysis: Revenue, Earnings & Valuation

2.94 / 10

Underperform

Fundamental analysis rates MGX as Underperform with a 2.9/10 score. Strengths include PB‑ROE, cash‑to‑market and inventory turnover, while asset‑to‑market, fixed‑asset turnover and YoY revenue decline (‑51.8%) weigh heavily. Outlook remains guarded.

Analysis Checks(7/10)

Revenue-MV

Value-1.22

Score1/3

Weight12.44%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value-51.79

Score2/3

Weight-1.99%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.50%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.76%

1M Return1.69%

PB-ROE

Value-0.79

Score2/3

Weight15.61%

1M Return6.97%

Income tax / Total profit (%)

Value0.07

Score2/3

Weight2.21%

1M Return1.04%

Fixed assets turnover ratio

Value0.48

Score1/3

Weight-2.30%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.54%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight29.59%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight14.65%

1M Return5.94%

Is MGX fundamentally strong?

MGX scores 2.94/10 on fundamentals and holds a Premium valuation at present. Backed by its -44.67% ROE, -348.54% net margin, -0.58 P/E ratio, 0.32 P/B ratio, and 0.00% earnings growth, these metrics solidify its Underperform investment rating.